Gecacitinib Hydrochloride

盐酸吉卡昔替尼

Report date: 2026/05/06 20:02:28
NME

Base Information

Drug NameGecacitinib Hydrochloride
Drug Alias NameJacketinib盐酸杰克替尼Gecacitinib盐酸吉卡昔替尼Jaktinib hydrochloride +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase JAK1 inhibitorsTyrosine-protein kinase JAK3 inhibitors +[5] 
TargetsTyrosine-protein kinase JAK2Tyrosine-protein kinase JAK1Tyrosine-protein kinase JAK3 +[5] 
Therapy Area/IndicationsPlaque psoriasisCoronavirus Disease 2019 (COVID-19)Solid tumours +[19] 
Global Approved IndicationsPrimary Myelofibrosis
Approved Indications in ChinaPrimary Myelofibrosis
Original Approved Country/TerritoryMainland China
Original Approved Date2025/05/27
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSuzhou Zelgen Biosciences Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesZejing Pharmaceutical (Zhejiang) Co LtdSuzhou Zelgen Biopharmaceuticals Co LtdShanghai Zejing Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisCoronavirus Disease 2019 (COVID-19)Solid tumours +[16] 
Inactive IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesPneumonia

Other Information

ATC CodeN/A
Related LinksDrugBank